A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging.

Trial Profile

A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Elacestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 20 Dec 2017 Planned primary completion date changed from 1 May 2018 to 1 Feb 2018.
    • 09 Dec 2017 Results (n=16) visualization and quantification of residual ER-binding with FES-PET after treatment with elacestrant, were presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 04 Dec 2017 According to a Radius Health Inc. media release, data from the study will be presented at the San Antonio Breast Cancer Symposium Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top